151 related articles for article (PubMed ID: 10599360)
1. Vasospasmolytic therapy in patients with SSC.
Jünger M; Schlez A; Klyscz T; Steins A; Hahn M
Adv Exp Med Biol; 1999; 455():305-7. PubMed ID: 10599360
[No Abstract] [Full Text] [Related]
2. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.
Faggioli P; Giani L; Mazzone A
Clin Exp Rheumatol; 2006; 24(2):220-1. PubMed ID: 16762173
[No Abstract] [Full Text] [Related]
3. Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy: a pilot study.
Shah P; Murray AK; Moore TL; Herrick AL
J Rheumatol; 2011 Sep; 38(9):2079-80. PubMed ID: 21885525
[No Abstract] [Full Text] [Related]
4. [Iloprost for the treatment of systemic sclerosis].
Hachulla E; Launay D; Hatron PY
Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study.
Cutolo M; Ferrone C; Pizzorni C; Soldano S; Seriolo B; Sulli A
J Rheumatol; 2010 Jun; 37(6):1174-80. PubMed ID: 20436070
[TBL] [Abstract][Full Text] [Related]
6. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
[TBL] [Abstract][Full Text] [Related]
7. Is iloprost effective in secondary Raynaud's phenomenon?
Lustig N; Rada G
Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
Lamprecht P; Schnabel A; Gross WL
Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
[No Abstract] [Full Text] [Related]
9. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
[TBL] [Abstract][Full Text] [Related]
10. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost.
Foti C; Cassano N; Conserva A; Coviello C; De Meo M; Vena GA
Clin Exp Dermatol; 2004 May; 29(3):321-3. PubMed ID: 15115528
[No Abstract] [Full Text] [Related]
11. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test.
Kido M; Takeuchi S; Hayashida S; Urabe K; Sawada R; Furue M
Br J Dermatol; 2007 Oct; 157(4):690-7. PubMed ID: 17640308
[TBL] [Abstract][Full Text] [Related]
12. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
15. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
Kamata Y; Kamimura T; Iwamoto M; Minota S
Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
[No Abstract] [Full Text] [Related]
16. The Application of Fluorescence Optical Imaging in Systemic Sclerosis.
Pfeil A; Drummer KF; Böttcher J; Jung C; Oelzner P; Renz DM; Franz M; Hansch A; Wolf G
Biomed Res Int; 2015; 2015():658710. PubMed ID: 26357658
[TBL] [Abstract][Full Text] [Related]
17. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis.
Cutolo M; Ruaro B; Pizzorni C; Ravera F; Smith V; Zampogna G; Paolino S; Seriolo B; Cimmino M; Sulli A
J Rheumatol; 2014 May; 41(5):881-6. PubMed ID: 24692525
[TBL] [Abstract][Full Text] [Related]
18. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
19. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
Antcliff AC; Bouhoutsos J; Martin P; Morris T
Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
[No Abstract] [Full Text] [Related]
20. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
